AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Primary Outcome Measures

1. Relative change in body weight
   Measured as percentage (%) change in body weight.
2. Change in apnoea-hypopnoea index (AHI)
   Measured as events/hour.

Secondary Outcome Measures

1. Relative change in AHI
   Measured as percentage change in AHI.
2. Achievement of 50% reduction in AHI (Yes/No)
   Measured as number of participant.
3. Achievement of: AHI less than (<) 5
   Measured as number of participants.
4. Achievement of: AHI 5-14 with Epworth Sleepiness Scale (ESS) ≤ 10 (Yes/No)
   Measures as number of participants
5. Change in sleep apnoea specific hypoxic burden (SASHB)
   Measured as percentage minutes per hour (%min/h).
6. Change in ESS score
   Measured as score on a scale. ESS measures the level of daytime sleepiness or average sleep propensity. The measure consists of 8 items yielding one total score. Total score ranges from 0-24. Higher scores indicate higher sleepiness or average sleep propensity in daily life.
7. Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Sleep-Related Impairment 8a score
   Measured as score on a scale. PROMIS-SRI measures perceptions of alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The measure consists of 8 items each rated on a 5-point scale ranging from &quot;not at all&quot; to &quot;very much&quot;. Individual item scores will be combined and converted to a T-score using a response pattern scoring approach. The T-score standardises the raw score to a distribution with a mean of 50 and standard deviation of 10. Total score (T-score range): Sleep-related impairment (ranging approximately from 30-80.1). Higher scores indicate more sleep-related impairment.
8. Change in PROMIS Short Form v1.0 Sleep Disturbance 8b score
   Measured as score on a scale. PROMIS-SD measures perceptions of sleep quality, sleep depth, and restoration associated with sleep. The measure consists of 8 items each rated on a 5-point scale ranging from &quot;not at all&quot; to &quot;very much,&quot; &quot;never&quot; to &quot;always,&quot; or &quot;very poor&quot; to &quot;very good&quot;. Individual item scores will be combined and converted to a T-score using a response pattern scoring approach. The T-score standardises the raw score to a distribution with a mean of 50 and standard deviation of 10. Total score (T-score range): Sleep disturbance (ranging approximately from 30-80.1). Higher scores indicate more sleep disturbance.
9. Change in body weight
   Measured as kilogram (Kg).
10. Change in body mass index (BMI)
    Measured as kilograms per meter square (kg/m\^2).
11. Improvement in obstructive sleep apnoea (OSA) severity category: AHI < 5/hour = normal (Yes/No)
    Measured as number of participants.
12. Improvement in obstructive sleep apnoea (OSA) severity category: ≥ 5 and < 15/hour = mild (Yes/No)
    Measured as number of participants.
13. Improvement in obstructive sleep apnoea (OSA) severity category: ≥ 15 and < 30/hour = moderate (Yes/No)
    Measured as number of participants.
14. Improvement in obstructive sleep apnoea (OSA) severity category: ≥ 30/hour = severe (Yes/No)
    Measured as number of participants.
15. Change in waist circumference
    Measured as centimetre (cm).
16. Change in neck circumference
    Measured as cm.
17. Change in systolic blood pressure (SBP)
    Measured as millimetre of mercury (mmHg).
18. Change in diastolic blood pressure (DBP)
    Measured as mmHg.
19. Change in high-sensitivity C-reactive protein (hsCRP)
    Measured as ratio to baseline
20. Change in Total cholesterol
    Measured as ratio to baseline.
21. Change in High-density lipoprotein (HDL) cholesterol
    Measured as ratio to baseline.
22. Change in Low-density lipoprotein (LDL) cholesterol
    Measured as ratio to baseline.
23. Chage in Very low-density lipoprotein (VLDL) cholesterol
    Measured as ratio to baseline.
24. Change in Non-HDL cholesterol
    Measured as ratio to baseline.
25. Change in Triglycerides
    Measured as ratio to baseline.
26. Change in fasting plasma glucose
    Measured as millimoles per litre (mmol/L).
27. Change in glycated haemoglobin (HbA1c)
    Measured as % of HbA1c.
28. Number of Treatment emergent adverse events (TEAEs)
    Measured as events.
29. Number of Treatment emergent serious adverse events (TESAEs)
    Measured as Events.
30. Number of TEAEs leading to permanent treatment discontinuation
    Measured as events.